Ovarian Cancer: Research
(asked on 27th June 2025) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to increase research funding for (a) ovarian, (b) uterine and (c) other gynaecological cancers.
The Department invests in research through its research delivery arm, the National Institute for Health and Care Research (NIHR). In the period 2020/21 to 2024/25, the NIHR’s Academy and other programmes invested approximately £39 million across 50 gynaecological cancer research projects. The following table shows the number of awards and the value of the awards for each gynaecological cancer type:
Gynaecological cancer type | Number of awards | Awards value |
Cervical cancer | 17 | £15,200,000 |
Ovarian cancer | 17 | £6,300,000 |
Vulval cancer | 1 | £3,700 |
Womb (uterine) cancer | 10 | £3,600,000 |
More than 1 gynaecological type | 5 | £10,000,000 |
Grand total | 50 | £39,000,000 |
Additionally, the NIHR’s Research Delivery Network, which enables the health and care system to attract, optimise, and deliver research across England, and has supported 123 commercial studies and 148 non-commercial studies for gynaecological cancers covering the same period.
The NIHR funds research in response to proposals received. The NIHR continues to welcome high quality, high impact funding applications for research into any aspect of human health and care, including all gynaecological cancers.